| Patient | Elvis Presley |
|---|---|
| Date of birth | 1987-01-08 |
| Identifiers | MRN HR-ML003-SYN; SSN (made up) 000-03-4417 |
| Document date | 2026-08-07 |
| Author | Coleman Ashby-Nakagawa, MD |
| Custodian | St. Posthumous Health Center |
Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.
Three-week review on buprenorphine, before a Las Vegas engagement. [S]
Mr. Presley returns three weeks after starting buprenorphine. Withdrawal settled on the first day, and he has taken 16 mg every morning since, with mild cravings in the evenings after rehearsals and no other opioid. He had weekly phone contact and two counseling sessions. He has taken diazepam 10 mg four times daily and no alprazolam. He used CPAP on 82% of nights, for an average of 6.1 hours, and is less sleepy in the afternoons (Epworth 9). His home blood pressure has averaged 128/82 on amlodipine with valsartan, without ankle swelling or dizziness. His bowels open every one to two days, so he has stopped the senna. He is anxious about the three-week Las Vegas engagement starting in twelve days. He had to leave for a rehearsal before giving a urine sample. [S]
| Element | Detail |
|---|---|
| Buprenorphine | 16 mg daily for three weeks; mild evening cravings; no other opioid |
| Diazepam | 40 mg a day; no alprazolam |
| CPAP | 82% of nights, 6.1 hours average; Epworth 9 |
| Home blood pressure | Average 128/82 |
| Bowels | Every one to two days; senna stopped |
| Mood | PHQ-9 6; GAD-7 8 |
| System | Result | Finding |
|---|---|---|
| Constitutional | Negative | Energy better |
| Cardiovascular | Negative | No ankle swelling, dizziness or palpitations |
| Gastrointestinal | Negative | Bowels regular; no nausea |
| Psychiatric | Positive | Anxious about the engagement; no thoughts of suicide or self-harm |
4 systems reviewed. [S]
| Medication | Frequency | Route | Dates | Status | Evidence |
|---|---|---|---|---|---|
| Hydromorphone 4 mg oral tablet, prescribed elsewhere as one tablet every four to six hours as needed for back and neck pain; taking about five a day (20 mg, 100 MME); continued by this clinic only, at the verified dose and seven days at a time, until the addiction medicine consultation | Up to five tablets a day; seven-day supply | Oral route | 2026-07-10 to 2026-07-17 | completed | S |
| Oxycodone 10 mg and acetaminophen 325 mg oral tablet, prescribed by a second prescriber; taking about three a day (45 MME); continued by this clinic only, seven days at a time, until the consultation | Up to three tablets a day; seven-day supply | Oral route | 2026-07-10 to 2026-07-17 | completed | S |
| Diazepam 10 mg oral tablet, one tablet three times daily, prescribed elsewhere for anxiety; continued by this clinic only, seven days at a time | One tablet three times daily; seven-day supply | Oral route | 2026-07-10 to 2026-07-17 | completed | S |
| Alprazolam 1 mg oral tablet, up to three a day as needed, prescribed by a fourth prescriber while on tour; continued by this clinic only, at the verified dose, seven days at a time | Up to three tablets a day; seven-day supply | Oral route | 2026-07-10 to 2026-07-17 | completed | S |
| Phentermine 37.5 mg oral tablet each morning, prescribed by a weight clinic; stopped today because of high blood pressure and his glaucoma | Stopped | Oral route | 2026-07-10 to 2026-07-10 | completed | S |
| Latanoprost 0.005% eye drops, one drop in each eye at bedtime, prescribed by his ophthalmologist | One drop in each eye at bedtime | Ophthalmic route | 2026-07-10 | active | S |
| Naloxone 4 mg nasal spray, one spray into one nostril for a suspected overdose, repeated in the other nostril after two to three minutes if needed; two-pack, with a second for the tour bag | One spray for a suspected overdose; call 911 | Nasal route | 2026-07-10 | active | S |
| Polyethylene glycol 3350, 17 g powder in a glass of water once daily | 17 g in water once daily | Oral route | 2026-07-10 | active | S |
| Senna 8.6 mg oral tablet, two tablets at bedtime | Two tablets at bedtime | Oral route | 2026-07-10 to 2026-08-07 | completed | S |
| Buprenorphine 8 mg and naloxone 2 mg sublingual film, two films (16 mg) under the tongue once daily, which may be split into one film twice daily; started in the office at the consultation; seven-day supplies at first, from this clinic only | Two films once daily, or one film twice daily | Sublingual route | 2026-07-17 | active | S |
| Diazepam 10 mg oral tablet, one tablet four times daily (40 mg a day), replacing both diazepam 10 mg three times daily and alprazolam; held steady until buprenorphine is stable | One tablet four times daily; seven-day supply | Oral route | 2026-07-17 to 2026-08-07 | completed | S |
| Diazepam 10 mg oral tablet, one tablet three times daily, with diazepam 2 mg tablets for the taper steps; dispensed two weeks at a time | One tablet three times daily with the 2 mg tablets as scheduled | Oral route | 2026-08-07 | active | S |
| Diazepam 2 mg oral tablet on the written taper schedule: three a day (36 mg a day in all) from the three-week visit, one a day (32 mg) from the ten-week visit, stopped at four months (30 mg) | Per the written taper schedule | Oral route | 2026-08-07 to 2026-10-28 | completed | S |
| Amlodipine 5 mg and valsartan 160 mg oral tablet, one tablet daily | One tablet daily | Oral route | 2026-07-17 | active | S |
| Tirzepatide 2.5 mg/0.5 mL auto-injector, 2.5 mg under the skin once weekly | 2.5 mg once weekly | Subcutaneous route | 2026-08-07 to 2026-09-23 | completed | S |
| Allergy | Reaction | Status | Evidence |
|---|---|---|---|
| No known allergy | active | S |
| Date | Measure | Value | Unit | Provenance |
|---|---|---|---|---|
| 2026-08-07 | Body height | 183 | cm | S |
| 2026-08-07 | Body weight | 108.2 | kg | S |
| 2026-08-07 | Body mass index (BMI) [Ratio] | 32.3 | kg/m2 | S |
| 2026-08-07 | Systolic blood pressure | 128 | mm[Hg] | S |
| 2026-08-07 | Diastolic blood pressure | 82 | mm[Hg] | S |
| 2026-08-07 | Heart rate | 76 | /min | S |
| 2026-08-07 | Respiratory rate | 14 | /min | S |
| 2026-08-07 | Body temperature | 36.7 | Cel | S |
| 2026-08-07 | Oxygen saturation in Arterial blood by Pulse oximetry | 97 | % | S |
| Date | Measure | Value | Unit | Reference range | Flag | Provenance |
|---|---|---|---|---|---|---|
| 2026-08-07 | Potassium [Moles/volume] in Serum or Plasma | 4.4 | mmol/L | 3.5-5.1 mmol/L | Normal | S |
| 2026-08-07 | Creatinine [Mass/volume] in Serum or Plasma | 1.04 | mg/dL | 0.74-1.35 mg/dL | Normal | S |
| 2026-08-07 | Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 2021)/1.73 sq M | 94 | mL/min/{1.73_m2} | >=60 mL/min/1.73 m² | Normal | S |
| 2026-08-07 | Patient Health Questionnaire 9 item (PHQ-9) total score [Reported] | 6 | {score} | S | ||
| 2026-08-07 | Generalized anxiety disorder 7 item (GAD-7) total score [Reported.PHQ] | 8 | {score} | S |
Vital signs recorded on 2026-08-07; see the Vital Signs section. [S]
| System | Finding |
|---|---|
| General | Calm and alert; blood pressure 128/82, pulse 76; weight 108.2 kg |
| Eyes | Pupils 3 mm, equal and reactive |
| Neurological | No tremor or sedation |
| Problem | Clinical status | Verification | Code | Provenance |
|---|---|---|---|---|
| Fatigue, weight gain of about 14 kg in two years, constipation with a bowel movement every five to seven days, loud snoring with daytime sleepiness, and high blood pressure readings, in a man taking two opioids, two benzodiazepines and an appetite suppressant from five prescribers; under evaluation with addiction medicine, a sleep study and home blood pressure readings | resolved | confirmed | R53.83 | S — Synthetic presenting problem anchored to the documented prescribed drugs and weight gain; superseded when the consultation and tests made the diagnoses. |
| Obesity, class 1 (BMI 32.5), with prediabetes (hemoglobin A1c 5.8%); recorded without stigma; weight gain began with long touring schedules, night eating after shows and an appetite suppressant that stopped working | active | confirmed | E66.811 | S — Synthetic modern diagnosis anchored to his documented weight gain. |
| Glaucoma secondary to steroids, both eyes, mild stage, after an acute angle-closure episode treated years ago; intraocular pressure controlled on latanoprost under his ophthalmologist; anticholinergic and sympathomimetic drugs to be avoided | active | confirmed | H40.63X1 | S — Synthetic modern diagnosis anchored to his documented glaucoma and the retrospective interpretation of it as steroid-induced; not a claim about his real eyes. |
| Opioid use disorder, severe, with prescription opioids from more than one prescriber (seven DSM-5-TR criteria, tolerance and withdrawal counted because the opioids were not taken as prescribed); on buprenorphine from the consultation; synthetic modern episode linked to his documented withdrawal from narcotic drugs and prescribed painkillers | active | confirmed | F11.20 | S — Synthetic modern diagnosis made at the addiction medicine consultation; person-first language; not a claim about his real diagnosis. |
| Sedative, hypnotic, or anxiolytic use disorder (benzodiazepines), moderate (five DSM-5-TR criteria), with two benzodiazepines from two prescribers; combined into diazepam and tapering slowly; synthetic modern episode linked to his documented prescribed sedatives | active | confirmed | F13.20 | S — Synthetic modern diagnosis made at the consultation; not a claim about his real diagnosis. |
| Hypertension, stage 2, confirmed by a home average of 146/94 a week after stopping phentermine; ECG and urine albumin normal | active | confirmed | I10 | S — Synthetic modern diagnosis confirmed with home readings, anchored to his documented hypertension. |
| Obstructive sleep apnea, moderate (apnea-hypopnea index 26 an hour, central apnea index 4, oxygen nadir 80% on in-laboratory polysomnography), worsened by opioids and benzodiazepines; on CPAP | active | confirmed | G47.33 | S — Synthetic modern diagnosis from a synthetic sleep study. |
| Opioid-induced constipation (Rome IV), improving after the change to buprenorphine; no alarm features | active | confirmed | K59.03 | S — Synthetic modern diagnosis anchored to his documented blockage of the colon; not a claim about megacolon. |
Protocol monitoring: items the monitoring protocol calls for at this visit. [S]
| Domain | Measure | Interval | Status | Detail |
|---|---|---|---|---|
| Medication safety | Buprenorphine dose, withdrawal symptoms, cravings and other opioid use | Every visit; weekly contact in the first month | Completed today | 16 mg daily; no withdrawal after the first day; mild evening cravings; weekly calls done |
| Medication safety | Prescription drug monitoring program check | Before every controlled-substance prescription | Completed today | Only this clinic's prescriptions |
| Laboratory | Urine drug test, including buprenorphine metabolite and fentanyl | At the start of treatment, then about monthly while doses are changing | Deferred | Not collected: he left for a rehearsal before giving a sample. No harm is evident: the monitoring program shows only this clinic's prescriptions and he reports no other use. Corrective action: sample to be collected at the start of the next visit |
| Medication safety | Naloxone on hand and people taught to use it | Every visit | Completed today | At home and in the tour bag |
| Medication safety | Diazepam dose, withdrawal symptoms (anxiety, insomnia, tremor, sweats) and taper pace | Every two to four weeks during the taper | Completed today | First step today, 40 to 36 mg a day (10%); no withdrawal symptoms |
| Survey | Suicide-risk review, safety plan, means safety (locked medicines and firearms) and the 988 Suicide & Crisis Lifeline | Every visit | Completed today | No thoughts of suicide or self-harm; safety plan reviewed; firearms and medicines locked |
| Survey | Mood (PHQ-9) and anxiety (GAD-7) | At baseline, four to six weeks after a change in treatment, then at each review | Completed today | PHQ-9 6 (item 9 scored 0); GAD-7 8 |
| Examination | Office and home blood pressure (target below 130/80) | Every visit | Completed today | Office 128/82; home average 128/82 |
| Laboratory | Potassium and creatinine after starting an angiotensin receptor blocker | Two to four weeks after starting, then every six months | Completed today | Potassium 4.4, creatinine 1.04 three weeks after starting valsartan |
| Examination | Weight and BMI | Every visit | Completed today | 108.2 kg, BMI 32.3 |
| Medication safety | Tirzepatide tolerance: nausea, vomiting, constipation, abdominal pain | At each dose step | Completed today | Baseline before the first dose: no nausea; bowels every one to two days |
| Survey | CPAP adherence (device data) and sleepiness (Epworth, recorded as narrative) | Within the first 30 to 90 days, then at each review | Completed today | 82% of nights, 6.1 hours; Epworth 9 |
| Self-management | Bowel frequency, straining and alarm features | Every visit | Completed today | Every one to two days; senna stopped |
| Examination | Glaucoma: drop adherence, eye symptoms, medicines that raise eye pressure or close the angle, and ophthalmology follow-up | Every visit; ophthalmology every three to six months while recently controlled | Completed today | Drops nightly; no eye symptoms; no new drug that affects eye pressure |
| Self-management | Touring plan: one named pharmacy, video visits while away, CPAP and naloxone in the tour bag, no dose change in the week before an engagement | Before each engagement or tour | Completed today | Written plan for the Las Vegas engagement: one pharmacy, weekly video visits, travel CPAP, naloxone, no taper step while away |
Goal progress:
Guideline basis: CDC Clinical Practice Guideline for Prescribing Opioids for Pain — United States, 2022 (2022); The ASAM National Practice Guideline for the Treatment of Opioid Use Disorder: 2020 Focused Update (2020); Joint Clinical Practice Guideline on Benzodiazepine Tapering: Considerations When Risks Outweigh Benefits (2025); 2025 AHA/ACC/AANP/AAPA/ABC/ACCP/ACPM/AGS/AMA/ASPC/NMA/PCNA/SGIM Guideline for the Prevention, Detection, Evaluation and Management of High Blood Pressure in Adults (2025); AGA Clinical Practice Guideline on Pharmacological Interventions for Adults With Obesity (2022); Tirzepatide for the Treatment of Obstructive Sleep Apnea and Obesity (2024); Treatment of Adult Obstructive Sleep Apnea with Positive Airway Pressure: An American Academy of Sleep Medicine Clinical Practice Guideline (2019); CMID: Clinical Monitoring Intelligence Database, hypertension, glaucoma, and depression, bipolar, and mood disorders monographs (2026)
Follow-up: Preventive visit next week. Weekly video visits during the engagement. Ten-week review after he returns. Next scheduled visit 2026-08-14: periodic adult preventive visit. [S]